Autolus is a clinical-stage, biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products to combat cancer. The company was founded in 2014 and is headquartered in London, the United Kingdom.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Autolus Therapeutics news
05.05.2022
Autolus Therapeutics' GAAP loss for 3 months of 2022 was $44.517 million, up 39.1% from $31.993 million in the prior year. Licensed revenues decreased 38.3% to $166 million from $269 million a year earlier.
Source: 
autolus.gcs-web.com
autolus.gcs-web.com
31.03.2022
EMA has granted orphan drug status to Autolus Therapeutics' acute lymphoblastic leukemia drug CAR T. The status allows to reduce production costs and facilitates the procedure of drug approval. A key advantage is the exclusivity of the drug in the EU for 10 years after EMA approval.
Source: autolus.gcs-web.com
autolus.gcs-web.com
10.03.2022
Autolus Therapeutics' IFRS loss for 2021 was $142.096 million, up 0.01% from $142.094 million in the prior year. Licensed revenues decreased 44.1% to $0.823 million compared to $1.473 million a year earlier.
Source: autolus.gcs-web.com
autolus.gcs-web.com
03.11.2021
Autolus Therapeutics' GAAP loss for 9M 2021 was $100.43 million, up 1.2% from $99.233 million in the prior year. Revenue increased 6.2-fold to $1,507 million from $0.242 million a year earlier.
Source: autolus.gcs-web.com
autolus.gcs-web.com
General information
| Company name | Autolus Therapeutics |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | Forest House 58 Wood Lane White City London W12 7RZ United Kingdom |
| Mailing address | Forest House 58 Wood Lane White City London W12 7RZ United Kingdom |
| Website | www.autolus.com |
| Information disclosure | www.sec.gov |
English (US) 